On day 11, the patient exhibited intermittent tachypnea, with no obvious improvement in clinical signs
Mild symptoms are heartburn, bloating, burping, nausea, or intense fullness
SEMAGLUTIDE improves hepatic steatosis, disease activity and promotes the resolution of metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis, while also promoting weight loss and enhancing metabolic health
HHS, hyperosmolar hyperglycemic syndrome
while all three treated groups had benefits as assessed by looking at liver fat area and triglycerides, the Sema + -MSTN/-ActA combination (which had the largest decreases in overall body fat composition) also had the largest benefits in terms of these liver measures (Fig